Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a Resource-Constrained Setting in South India
Arun Krishnan MP, Nandini Devi R, Praveen K Shenoy, Shoaib Nawaz, Abhilash Menon · 2026
Read Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Outcomes and Subsequent Treatment Patterns from a Resource-Constrained Setting in South India by Arun Krishnan MP, Nandini Devi R, Praveen K Shenoy, Shoaib Nawaz, Abhilash Menon (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13574551.txt.
Description
Five cancer doctors led by Arun Krishnan MP report results for a lower dose of the drug pazopanib in kidney cancer that has spread. In South India, costly immune drugs are out of reach for many patients, so this older drug stays in wide use. The study reviewed eighty-four patients given half the standard dose as their first treatment.
Most patients gained some control of their disease at the first check. Time before the cancer grew again was near nine months, and typical survival was over two years. Side effects were mostly mild, and few stopped treatment. The team calls the lower dose a workable, safer option where funds are tight.
Catalog record
| CREATOR | Arun Krishnan MP, Nandini Devi R, Praveen K Shenoy, Shoaib Nawaz, Abhilash Menon |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |